Head-to-head evidence
albuterol / budesonide vs fluticasone propionate
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Glucocorticoid receptor · full Asthma pipeline
albuterol / budesonide · Airsupra
Marketed by AstraZeneca
NCT03769090 · Phase 3 · completed
Participants were randomized and quadruple-blinded across two budesonide/albuterol groups and an active albuterol comparator, with 3,132 randomized participants. The primary clinical endpoint was met for both doses: severe exacerbations occurred in 207/1,013 versus 266/1,014 participants for high-dose treatment (hazard ratio 0.733, p<0.001) and 241/1,054 versus 276/1,056 for low-dose treatment (hazard ratio 0.835, p=0.041).
Next expected readout: February 2027 · NCT06422689 (registry estimate)
fluticasone propionate
Marketed by GlaxoSmithKline
NCT00920959 · Phase 3 · completed
The study was randomized and double-blind, included 908 participants, and compared fluticasone-based treatments with placebo. However, its primary measure was a pulmonary-function surrogate rather than a hard clinical or endoscopic outcome, and the registry does not report whether the primary comparison was met.
Next expected readout: September 2027 · NCT07664527 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol / budesonide's landscape · fluticasone propionate's landscape